GASTROINTESTINAL CANCER

NCCTG胃肠道(GI)癌症项目汇集了来自所有肿瘤学学科的专家，目标如下：1.尽可能提高治愈率或延长生存期/改善患者的生活质量。A)启动/领导GI Intergroup/NCCTG III期临床试验。B)参加由其他肿瘤学小组领导的GI组间试验。C)基于梅奥诊所第一阶段计划或其他地方与NCCTG新型治疗委员会合作开发的最有希望的胃肠道癌症治疗策略，快速启动/完成试点研究和第二阶段试验。这一战略体现在八个主要胃肠道部位的有针对性的研究的表现上。D)综合多种模式(外科、放射和内科肿瘤学)，并让适当的模式委员会参与试验设计和实施。2.设计可在患者家附近实施的治疗方法，并在适当的情况下转介到专门中心。A)在研究和社区基础之间建立以研究为导向的伙伴关系。B)在NCCTG会议及其周围举办教育研讨会。3)通过研究预后决定因素、影响疾病进展的因素和个体对化疗的反应(即转译研究)，加深对肿瘤生物学和宿主反应的了解。A)与拥有相关科学专业知识的梅奥诊所研究人员进行互动。B)与其他地方的实验室调查人员合作。4.利用已完成研究中广泛的NCCTG数据库，回答临床实践、前瞻性试验分析或文献中出现的问题。5.监测和改善患者的生活质量(QOL)及评估工具。6.针对我们研究中出现的问题，通过设计新的试验范例和系统来优化数据收集，推动临床试验研究领域的发展。7.吸引多学科肿瘤学团队的不同成员参与致力于扩大癌症护理视野的合作。本申请将根据我们在上一次资助期间取得的成绩，重点关注NCCTG GI计划的过去、现在和预测的未来。我们将描述基于上述哲学原则定义NCCTG GI计划的具体方案方法。我们将专注于我们在前一个授权期(目前)取得的成就，并规划主题和概述新的倡议，我们希望这些新倡议将定义我们在下一个授权期(未来)的计划。

The NCCTG Gastrointestinal (GI) Cancer Program brings together specialists from all oncology disciplines with the following goals: 1. To improve cure rates when possible or extend survival/improve patient quality of life. a) Initiation/leadership of GI Intergroup/NCCTG phase III clinical trials. b) Participation in GI Intergroup trials led by other oncology groups. c) Rapid initiation/completion of Pilot Studies and Phase II trials, based on the most promising GI cancer treatment strategies developed in the Mayo Clinic Phase I program or elsewhere in collaboration with the NCCTG Novel Therapeutics Committee. This strategy manifests itself in the performance of targeted research studies across the eight primary GI tract sites. d) Integration of multiple modalities (surgery, radiation, and medical oncology) and participation of the appropriate modality committees in trial design and conduct. 2. To devise therapies that an be administered in proximity to the patient's home, with referral to specialized centers when approprite. a) By forging a research-driven partnership between the research and community bases. b) By conducting education symposia based in and around NCCTG meetings. 3) To further the understanding of tumor biology and host response through the investigation of prognostic determinants, factors influencing disease progression, and individual responses to chemotherapy (i.e. translational research). a) Interaction with Mayo Clinic researchers with expertise in correlative science. b) Collaboration with laboratory-based investigators elsewhere. 4. To utilize the extensive NCCTG database in completed studies to answer questions arising in clinical practice, from analyses of prospective trials, or from the literature. 5. To monitor and improve patient quality of life (QOL) and the tools to assess QOL. 6. To advance the field of clinical trials research by design of new trial paradigms and systems for optimal data collection in response to issues arising from our studies. 7. To entice involvement from diverse members of the multi-disciplinary oncology team in collaborations dedicated to extending the horizons of cancer care. This application will focus on the past, present, and projected future of the NCCTG GI Program based upon our accomplishments during the last grant period. We will delineate specific programmatic approaches that define the NCCTG GI Program based on the philosophical principles noted above. We will concentrate on our accomplishments in the prior grant period (present), and project the themes and outline the new initiatives that we hope will define our program in the next grant period (future).